Labrune S, Huchon G
Université de Paris René-Descartes, hôpital Ambroise-Paré, service de pneumologie, Boulogne.
Rev Prat. 1991 May 11;41(14):1275-7.
In fibrosing pneumonitis, respiratory insufficiency is due to both fibrosis and inflammation induced pulmonary fibrosis. There is no treatment that can suppress fibrosis, so the current treatment of fibrosing pneumonitis--corticosteroid and/or immunosuppressive drugs--aims at reducing pulmonary inflammation and thus at slowing down the development of fibrosis which cannot regress. Therefore, it is necessary to determine the respective parts of inflammation, potentially reversible, and of fibrosis which is not. Most of the time, respiratory insufficiency cannot be prevented and requires long-term oxygen therapy. In a few patients, lung transplantation must be discussed.
在纤维化性肺炎中,呼吸功能不全是由纤维化以及炎症引发的肺纤维化所致。目前尚无能够抑制纤维化的治疗方法,因此,纤维化性肺炎当前的治疗手段——使用皮质类固醇和/或免疫抑制药物——旨在减轻肺部炎症,从而减缓无法逆转的纤维化进程。所以,有必要明确炎症(可能具有可逆性)和纤维化(不可逆)各自所起的作用。大多数情况下,呼吸功能不全无法预防,需要长期进行氧疗。少数患者则必须考虑肺移植。